CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
By B. Lannutti, S. A. Meadows, S. E. Herman, A. Kashishian, B. Steiner, A. Johnson, J. Byrd, J. Tyner, M. Loriaux, M. Deininger and 4 more. Blood, 2011
777 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/2078fde40c9eb4c9bb30de9665e4fb130cfe0838
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
Citations in the corpus
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. (2014, background): “Idelalisib (GS-1101, CAL-101, 5-fluoro-3-phenyl-2-[(S)-1-(9Hpurin-6-ylamino)-propyl]-3H-quinazolin-4-one) is a potent smallmolecule inhibitor that is highly specific for PI3Kd.(10) In lymphoid cell lines and primary patient samples, idelalisib abrogates PI3K/Akt signaling and promotes apoptosis.”
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia (2014, neutral): “Infusion-related reaction 17 (15) 0 30 (28) 4 (4)”
- The PI3K/AKT Pathway as a Target for Cancer Treatment. (2016, background): “Idelalisib (CAL-101, GS-1101) is an oral, first-inclass, highly selective inhibitor of p110δ with proapoptotic activity in B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia (CLL) cell lines (83, 84), as well as in Hodgkin’s lymphoma cell lines (85).”